REMEDIUMREMEDIUM1561-59362658-3534Joint-Stock Company Chicot147710.32687/1561-5936-2022-26-4-347-356Original ArticleLaboratory monitoring of successful COVID-19 as part of the in-depth medical care project «Healthy Moscow»KomarovA. G.agrkomarov@rambler.ruLatypovaM. F.-SlutskyE. A.-BezymyannyA. S.-Diagnostic Center (Laboratory Research Center) of Moscow Healthcare DepartmentResearch Institute for Healthcare Organization and Medical Management of Moscow Healthcare DepartmentDirectorate for the coordination of the activities of medical organizations of Moscow Healthcare Department1512202226434735606122022Copyright © 2022,2022Introduction. After COVID-19, survivors often report post-COVID syndrome (PCS), which presents with a wide range of new, recurring, or ongoing symptoms lasting weeks or months after exposure to SARS-CoV-2. PCS is a poorly understood condition due to chronic, mild inflammation theorized as a pathophysiological mechanism.Aim. Our goal is to search for biomarkers for accurate identification of PCD, its treatment and prevention in men of different ages who recovered from COVID-19 as a result of SARS-CoV-2 Delta and Omicron.Materials and methods. The study is based on data from a population cohort study of the health status of Muscovites aged 18 years and over during in-depth medical examinations. Participants had a history of a positive SARS-CoV-2 test result or a diagnosis of COVID-19 that was at least 60 days after recovery. He completed a list of laboratory tests: complete blood count, ESR (in 2022), D-dimer and 7 biochemical biomarkers. Men were divided into age groups: 18-39, 40-59, 60+ years old. We recorded the values of the norm, above the norm, critically above the norm, below the norm and critically below the norm.Results. Statistically significant laboratory parameters with abnormal values were determined: leukocytes, lymphocytes, monocytes, eosinophils, hemoglobin, platelets, D-dimer, cholesterol, LDL, CRP, ALT, AST, LDH, creatinine (p < 0.01%).Discussion. An abbreviated working list of laboratory biomarkers for the primary sorter of PKC in men of different age groups was developed: “18-39 years old” - cholesterol, LDL, ALT, AST and CRP (p < 1%); «40-59 years old» - cholesterol, LDL, D-dimer, CRP, ALT, AST and ESR (p < 1%); «60+ years old» - D-dimer, cholesterol, LDL, ESR, CRP, creatinine, AST, Їplatelets and leukocytes (p < 1%).Conclusion. Monitoring the values of the established list of biomarkers is effective for the initial adequate sorting of men after COVID-19 who need dispensary observation and rehabilitation.COVID-19SARS-CoV-2COVID-19SARS-CoV-2DeltaOmicronpost-COVID syndromein-depth medical examinationmale age groupsbiomarkersCBCESRD-dimercholesterollow-density lipoproteinC-reactive proteinalanine aminotransferaseaspartate aminotransferaselactate dehydrogenase, creatinineДельтаОмикронпост-COVID-19-синдромуглублённая диспансеризациямужские возрастные группыбиомаркерыобщий анализ кровиСОЭD-димерхолестеринлипопротеины низкой плотностиC-реактивный белокаланинаминотрансферазааспартатаминотрансферазалактатдегидрогеназакреатинин1.Shah W., Hillman T., Playford E. D. et al. Managing the long-term effects of covid-19: summary of NICE, SIGN, and RCGP rapid guideline // BMJ. 2021. Vol. 372. P. n136. DOI: 10.1136/bmj.n1362.Cares-Marambio K., Montenegro-Jimenez Y., Torres-Castro R. et al. Prevalence of potential respiratory symptoms in survivors of hospital admission after coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis // Chron. Respir. Dis. 2021. Vol. 18. P. 14799731211002240. DOI: 10.1177/147997312110022403.Rando H. M., Bennett T. D., Byrd J. B. et al. Challenges in defining Long COVID: striking differences across literature, electronic health records, and patient-reported information // medRxiv. 2021. DOI: 10.1101/2021.03.20.212538964.Dennis A., Wamil M., Alberts J. et al. Multiorgan impairment in low-risk individuals with post-COVID-19 syndrome: a prospective, community-based study // BMJ Open. 2021. Vol. 11, N 3. P. e048391. DOI: 10.1136/bmjopen-2020-0483915.Lu Y., Li X., Geng D. et al. Cerebral micro-structural changes in COVID-19 patients - an MRI-based 3-month follow-up study // EClinicalMedicine. 2020. Vol. 25. P. 100484. DOI: 10.1016/j.eclinm.2020.1004846.Miyazato Y., Morioka S., Tsuzuki S. et al. Prolonged and late-onset symptoms of coronavirus disease 2019 // Open Forum Infect. Dis. 2020. Vol. 7, N 11. P. ofaa507. DOI: 10.1093/ofid/ofaa5077.van den Borst B., Peters J. B., Brink M. et al.Comprehensive health assessment three months after recovery from acute COVID-19 // Clin. Infect. Dis. 2020. Vol. 73, N 5. P. e1089-e1098. DOI: 10.1093/cid/ciaa17508.Townsend L., Dowds J., O’Brien K. et al. Persistent poor health post-COVID-19 is not associated with respiratory complications or initial disease severity // Ann. Am. Thorac. Soc. 2021. Vol. 36, N 1. P. 41-44. DOI: 10.1513/AnnalsATS.202009-1175OC9.Cheung K. S., Hung I. F.N., Chan P. P.Y. et al. Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from a Hong Kong Cohort: systematic review and meta-analysis // Gastroenterology. 2020. Vol. 159, N 1. P. 81-95. DOI: 10.1053/j.gastro.2020.03.06510.Mao R., Qiu Y., He J. S. et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis // Lancet Gastroenterol. Hepatol. 2020. Vol. 5, N 7. P. 667-678. DOI: 10.1016/S2468-1253(20)30126-611.Henry B. M., de Oliveira M. H.S., Benoit S. et al. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis // Clin. Chem. Lab. Med. 2020. Vol. 58, N 7. P. 1021-1028. DOI: 10.1515/cclm-2020-036912.Liang L., Yang B., Jiang N. et al. Three-month follow-up study of survivors of Coronavirus disease 2019 after discharge //j. Korean Med. Sci. 2020. Vol. 35, N 47. P. e418. DOI: 10.3346/jkms.2020.35.e41813.Mandal S., Barnett J., Brill S. E. et al. Long-COVID’: a crosssectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID // Thorax. 2021. Vol. 76, N 4. P. 396-398. DOI: 10.1136/thoraxjnl-2020-21581814.Kim H. J., Hwang H., Hong H. et al. A systematic review and meta-analysis of regional risk factors for critical outcomes of COVID-19 during early phase of the pandemic // Sci. Rep. 2021. Vol. 11, N 1. P. 9784. DOI: 10.1038/S41598-021-89182-8.15.Xu P., Zhou Q., Xu J. Mechanism of thrombocytopenia in COVID-19 patients // Ann. Hematol. 2020. Vol. 99, N 6. P. 1205-1208. DOI: 10.1007/s00277-020-04019-016.Tan C., Huang Y., Shi F. et al. C-reactive protein correlates with CT findings and predicts severe COVID-19 early //j. Med. Virol. 2020. Vol. 92, N 7. P. 856-862. DOI: 10.1002/jmv.2587117.Marvisi M., Ferrozzi F., Balzarini L. et al. First report on clinical and radiological features of COVID-19 pneumonitis in a Caucasian population: factors predicting fibrotic evolution // Int. J. Infect. Dis. 2020. Vol. 99. P. 485-488. DOI: 10.1016/j.ijid.2020.08.05418.Liao B., Liu Z., Tang L. et al. Longitudinal clinical and radiographic evaluation reveals interleukin-6 as an indicator of persistent pulmonary injury in COVID-19 // Int. J. Med. Sci. 2021. Vol. 18, N 1. P. 29-41. DOI: 10.7150/ijms.4972819.Raman B., Cassar M. P., Tunnicliffe E. M. et al. Medium-term effects of SARS-CoV-2 infection on multiple vital organs, exercise capacity, cognition, quality of life and mental health, post-hospital discharge // EClinicalMedicine. 2021. Vol. 31. P. 100683. DOI: 10.1016/j.eclinm.2020.10068320.Mandal S., Barnett J., Brill S. E. et al. Long-COVID’: a crosssectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID // Thorax. 2021. Vol. 76, N 4. P. 396-398. DOI: 10.1136/thoraxjnl-2020-21581821.Sweeney T., Quispe R., Das T. et al. The use of blood biomarkers in precision medicine for the primary prevention of atherosclerotic cardiovascular disease: a review // Expert Rev. Precis. Med. Drug Dev. 2021. Vol. 6, N 4. P. 247-258. DOI: 10.1080/23808993.2021.193053122.Ulmer H., Kelleher C., Diem G. et al. Why Eve is not Adam: prospective follow-up in 149650 women and men of cholesterol and other risk factors related to cardiovascular and all-cause mortality //j. Womens Health. 2004. Vol. 13, N 1. P. 41-53. DOI: 10.1089/15409990432283644723.Kishaba T., Tamaki H., Shimaoka Y. et al. Staging of acute exacerbation in patients with idiopathic pulmonary fibrosis // Lung. 2014. Vol. 192, N 1. P. 141-149. DOI: 10.1007/s00408-013-9530-024.Kim H. J., Hwang H., Hong H. et al. A systematic review and meta-analysis of regional risk factors for critical outcomes of COVID-19 during early phase of the pandemic // Sci. Rep. 2021. Vol. 11, N 1. P. 9784. DOI: 10.1038/S41598-021-89182-8